A clinical study published in 2010 revealed that patients with head and neck squamous cell carcinoma treated with 1,25(OH)2D3 had significantly increased levels of CD4+ and CD8+ T cells in their tissues and a longer time to tumor recurrence [176]. Here, CD8A is linked to neoplasm.